Evidence map›Paper›PMID 26074965›Full record

ArticleJournal of cancer epidemiology2015

Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients.

Susie Bae, Hui-Li Wong, Jeanne Tie, Jayesh Desai, Kathryn Field, Suzanne Kosmider, Spiros Fourlanos, Ian Jones, Iain Skinner, Peter Gibbs

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.International journal of colorectal disease · 2020 · on this map
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Susie BaeRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Hui-Li WongRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Jeanne TieRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia ; Western Hospital, Footscray, VIC 3011, Australia.
Jayesh DesaiRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia ; BioGrid Australia, Melbourne, VIC 3050, Australia.
Kathryn FieldRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Suzanne KosmiderWestern Hospital, Footscray, VIC 3011, Australia.
Spiros FourlanosRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Ian JonesRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Iain SkinnerWestern Hospital, Footscray, VIC 3011, Australia.
Peter GibbsRoyal Melbourne Hospital, Melbourne, VIC 3050, Australia ; Western Hospital, Footscray, VIC 3011, Australia ; BioGrid Australia, Melbourne, VIC 3050, Australia.
The Royal Melbourne Hospital · AUWestern Hospital · AUFootscray Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5-101.2). The diabetes patients (21.6%, n = 241) were older than nondiabetes patients (median 74.0 versus 69.6, p = 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%, p = 0.002) but were equally likely to complete treatment (69.7 versus 67.7%, p = 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71-1.63) or overall survival (HR = 1.23, 95% CI 0.88-1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer.

Identifiers

PMID26074965
PMCPMC4436511
OpenAlexW1604845515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.